Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression.

The article presents a study which showed that more than 80% of the C/EBα-negative/low adenocarcinoma patients are positive for the expression of the oncogenic protein BMI1 and that this expression pattern has prognostic value. Topics discussed include results showing that a subset of C/EBPα-negative/low and BMI1-positive human adenocarcinomas is amenable to BMI1 pharmacological inhibition and BMI1 is required for lung tumor initiation and maintenance.